Image-Based H&E Biomarkers Profiling in Real-time

Rectangle 54-2

The Power of AI: Revolutionizing and Democratizing Cancer Diagnosis - Fortune Health 2022

Our Mission

Our mission is to leverage AI to profile, within minutes, a broad range of biomarkers from the H&E image alone. By doing so, we can overcome economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients.

Learn More

Experts say about us

“Imagene’s technology can unlock precise and crucial information in real-time, changing the way cancer is diagnosed and treated.”

Group 146-2

Dr. David Agus

Founding Director and CEO

Lawrence J. Ellison Institute for Transformative Medicine

"This is a breakthrough technology that has been tested in deep collaboration with the physicians of our pathology lab" 

Mask Group

Prof. Iris Barshak

Head of Pathology

Sheba Medical Center

“Unfortunately, we are so used to waiting a long time for molecular cancer testing while patients deteriorate, that such a breakthrough technology, enabling treatment initiation within a day is exceptional.”

Group-146-8

Prof. Ido Wolf

Director of Oncology

Tel Aviv Sourasky Medical Center

“The pathology dept. at Ichilov participates in research and development of many new and advanced technologies, but it is rarely that we see a direct and meaningful impact on patients’ lives. We are excited about the opportunity to partner with Imagene to improve quality of care and impact patients’ lives.”

Group 136

Prof. Dov Hershkovitz

Director of Pathology

Tel Aviv Sourasky Medical Center

"Cancer diagnosis focuses on pathological and molecular testing. I believe that no structure and assumptions should become a barrier to personal treatment. Imagene brings the potential of accurate, fast, actionable, standardized screening to all cancer patients."

Mask Group

Prof. Nir Peled, MD, PhD

Director of Oncology

Shaare Zedek Medical Center

“Our team is proud to be part of Imagene’s mission to leverage AI in the fight against cancer. The ongoing digitization of healthcare will reward medical providers, payers and patients with new ways of leveraging data to improve diagnoses, treatments and outcomes” 

Mask Group-2

Yodfat Buchris

Managing Director

Blumberg Capital

"After seeing the same type of transformation in the AI medical imaging space, we are certain that Imagene is well positioned to disrupt the pathology biomarkers space with its unique AI platform and data assets.”

Group 146

Eyal Gura

Tech Entrepreneur, Mentor & Private Investor

A New Standard for Biomarker ProfilingFrom Weeks to Minutes

Schedule a demo
bg-home-demo

Imagene for Research

Standardize, accelerate and reduce costs of drug development through deep learning for clinical trials

noto_test-tube

Clinical Trials

noto_microscope

Precision Oncology

noto_pill

Drug Development

Real-time Molecular Analysis

icon-real-time-diagnosis

Immediate Biomarker Profiling

icon-image-only

Image-based Only (no tissue required)

icon-accuracy-levels

Accuracy Levels of Gold Standard Tests

vector-home-clinical

Imagene in Numbers

Organs

Group 5

Models

Group 6
%

avg Sensitivity

Group 7
%

avg Specificity

Group 8
bg-home-numbers
img-technology

Our Technology

lmagene's state-of-the-art deep learning models have the capabilities of searching for all present phenotypic alterations and empowering the reporting of meaningful insights.

We make no assumptions. our models rely on prospective data and unsupervised learning to provide the highest sensitivity and specificity rates.

Book a Demo

Join our Partners

logo-partners-1 logo-partners-2 logo-partners-3
Learn More About Us
vector-jhome-partners-1
vector-jhome-partners-2